From the Journals

Testosterone Replacement Therapy and Prostate Cancer Risk


 

DISCLOSURES:

This study was funded by a consortium of testosterone manufacturers led by AbbVie Inc., with additional financial support from Endo Pharmaceuticals, Acerus Pharmaceuticals Corporation, and Upsher-Smith Laboratories. Bhasin, Lincoff, and Khera reported receiving grants and consulting and personal fees from various sources. The remaining authors disclosed no conflicts of interest.

A version of this article appeared on Medscape.com.

Pages

Recommended Reading

The fertile future of fertility technology
MDedge Endocrinology
Continuous glucose monitors for pregnant patients?
MDedge Endocrinology
Ketogenic diet short-term may benefit women with PCOS
MDedge Endocrinology
Premenstrual disorders may be preview of early menopause
MDedge Endocrinology
Testosterone treatment helps correct anemia in men with hypogonadism
MDedge Endocrinology
Lack of racial, ethnic diversity in cryopreserved donor sperm in the U.S.
MDedge Endocrinology
AI algorithm aids egg retrieval date during fertility treatment cycles
MDedge Endocrinology
Bipolar disorder may raise risk of polycystic ovarian syndrome
MDedge Endocrinology
What is the link between cellphones and male fertility?
MDedge Endocrinology
What’s the Disease Burden From Plastic Exposure?
MDedge Endocrinology